Drug discovery in advanced prostate cancer: translating biology into therapy. - Wikidata - thesis-toulmin - TriplyDB

Drug discovery in advanced prostate cancer: translating biology into therapy.

Drug discovery in advanced prostate cancer: translating biology into therapy.

http://www.wikidata.org/entity/Q38839110

about

Exploiting Epigenetic Alterations in Prostate Cancer.Induced protein degradation: an emerging drug discovery paradigm.Marine-derived chromopeptide A, a novel class I HDAC inhibitor, suppresses human prostate cancer cell proliferation and migration.Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells.Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance.Application of Liquid Biopsies in Cancer Targeted Therapy.Vinculin and filamin-C are two potential prognostic biomarkers and therapeutic targets for prostate cancer cell migration.Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and Androgen.SEC-induced activation of ANXA7 GTPase suppresses prostate cancer metastasis.Regulation of Androgen Receptor Activity by Transient Interactions of Its Transactivation Domain with General Transcription Regulators.The unidirectional hypoxia-activated prodrug OCT1002 inhibits growth and vascular development in castrate-resistant prostate tumors.Transcriptomic features of primary prostate cancer and their prognostic relevance to castration-resistant prostate cancer.Circulating vitamin D concentration and risk of prostate cancer: a dose-response meta-analysis of prospective studies.Disentangling PTEN-cooperating tumor suppressor gene networks in cancer.Recent Advances in Prostate Cancer Treatment and Drug Discovery.Sprouty2 loss-induced IL6 drives castration-resistant prostate cancer through scavenger receptor B1.HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutami Luteolin attenuates Wnt signaling via upregulation of FZD6 to suppress prostate cancer stemness revealed by comparative proteomics.Combined immunotherapy for advanced prostate cancer: Empowering the T cell army.The association of HIF-1α expression with clinicopathological significance in prostate cancer: a meta-analysis Generation of Whole-Genome Sequencing Data for Comparing Primary and Castration-Resistant Prostate Cancer

P2860

Q33755160-9669BAE2-7318-4AC5-B3E7-F5C6FD6626DC Q34545841-EDA47E67-9417-4868-B6D7-19CA1315BDCA Q37744742-28DDE4F6-6107-4520-8613-5CD0B2211AD2 Q38729033-3A5D2C59-C188-4C28-8EAF-A6991C197C6D Q39093352-C5E75E81-980E-4778-B18A-C659D0A87A56 Q42634073-EC068127-F4D4-445C-A5BB-057451816AA9 Q47152110-BC4B9D30-78A7-4DAC-ADCA-6BF0BF809586 Q47222084-727BF97B-BB73-40B7-86DD-89593C7D0038 Q47243959-F2993A3C-02FC-4C0C-BD48-0CA5E5854BEF Q47310629-7617651C-77CD-4FF2-A541-2EAF34C4D8E9 Q47763534-68832F6C-F686-4C33-9CDB-A88269981190 Q49231491-D99A8DAA-E4BE-49C0-B506-21B4553DC9C3 Q49540308-F1EC7C4B-81E6-406F-A596-55A1545776AD Q50227697-ED38DC3B-56FF-46A0-8CF4-D98F7C763DF4 Q54111821-028E7311-DA87-4572-BC3A-7891345B4A06 Q54982147-3DCFFAF6-732B-4931-9E73-652011504289 Q55004240-9026F965-CE44-467D-98F5-AB55BC2E8904 Q55383894-C2179D6C-618D-44FC-A781-68C0921EBE96 Q55527258-7AACFCD0-CCA9-4D95-9806-5EB91B8E30EF Q57107650-EEFC276B-108E-4063-9EFE-B6E8FEE4BAB9 Q57494437-8640FA94-72E7-4318-979A-8501F28D15FE

P2860

Drug discovery in advanced prostate cancer: translating biology into therapy.

http://www.wikidata.org/entity/Q38839110

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Drug discovery in advanced prostate cancer: translating biology into therapy.

@en

type

label

Drug discovery in advanced prostate cancer: translating biology into therapy.

@en

prefLabel

Drug discovery in advanced prostate cancer: translating biology into therapy.

@en

P1433

Q38839110-8D1B9BB7-91E6-43EA-A2B8-DA643ADD02FF

P1476

Q38839110-4144D6B0-26BC-4D34-8265-8D2E6DB5FBE8

P2093

Q38839110-2CD7EDEE-59F7-4923-ACD0-C95CDAC978CF

Q38839110-4E543843-4D17-46E1-B932-7CD12D1AAF27

Q38839110-8DE1CFE4-EA1D-4FFC-821E-01140E52A42F

Q38839110-97CBA002-F19B-439F-A039-A3ECA869EA9E

Q38839110-D3866361-E0C2-4E55-94A9-5A87397F1424

P2860

Q38839110-014670C6-5B82-40BF-BCC8-B8471C26F065

Q38839110-016A4D59-7526-4353-B5B7-FD12C5E66960

Q38839110-0180A59C-91BA-46D0-8953-392AFB22110C

Q38839110-0513F25C-4ADC-4D96-888E-203868BC2BE3

Q38839110-06136009-171E-47A8-A553-CF5BAC1E9E06

Q38839110-0A332E82-2420-4A53-A30F-A9DC3C73671C

Q38839110-0A7DDA43-C268-459F-ADF8-2BFF40EFA83E

Q38839110-0B8C7B6A-E466-462B-991E-69624748BE6D

Q38839110-0C8790FC-B855-455B-9BA3-9EE5E5E48011

Q38839110-0D275142-E953-4F4C-A2F1-F3DE766D669B

P2888

Q38839110-B838B98F-9802-4393-9F82-E51C365B14A9

P304

Q38839110-2D946D96-2DFC-4410-A5B1-B4E981A2A6CF

P31

Q38839110-E9CD69A9-7F65-4370-83F5-83750F7B2734

P356

Q38839110-8072C008-FC6B-48BB-9AD7-241F8BE8E185

P433

Q38839110-4670851A-1721-41F1-BED0-F698052C9469

P478

Q38839110-EA5E409B-2FFA-4FFE-AEE4-18F2E1A61AD5

P50

Q38839110-DCCCEB5E-CDBC-4E24-9CF4-4E6E2B9F5FCD

P577

Q38839110-16D3A62D-9094-4C8F-AA23-9808E448680A

P6179

Q38839110-934C9745-525C-43CE-A6F9-2B4DA1D83D6D

P698

Q38839110-E50B9054-F247-4BD2-9AEA-7AEB2D6A6560

P356

P1433

Nature Reviews Drug Discovery

P1476

Drug discovery in advanced prostate cancer: translating biology into therapy.

@en

P2093

Alan D Smith

http://www.w3.org/2001/XMLSchema#string

Bissan Al-Lazikani

http://www.w3.org/2001/XMLSchema#string

Johann S de Bono

http://www.w3.org/2001/XMLSchema#string

Roberta Ferraldeschi

http://www.w3.org/2001/XMLSchema#string

Timothy A Yap

http://www.w3.org/2001/XMLSchema#string

P2860

Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival

Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma

Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer

An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression

Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor

Quantitative comparison of EST libraries requires compensation for systematic biases in cDNA generation

A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer

RNA-Seq: a revolutionary tool for transcriptomics

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

Abiraterone in metastatic prostate cancer without previous chemotherapy

P2888

P304

699-718

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRD.2016.120

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-07-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1047174339

http://www.w3.org/2001/XMLSchema#string

P698

27444228

http://www.w3.org/2001/XMLSchema#string